Picture of IVERIC bio logo

ISEE — IVERIC bio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Iveric Bio Inc expected to post a loss of 29 cents a share - Earnings Preview

* Iveric Bio Inc  ISEE.OQ   ISEE.O  is expected to show a no
change in quarterly revenue when it reports results on November
1 (estimated). 
​* Refinitiv's mean analyst estimate for Iveric Bio Inc is for a
loss of 29 cents per share. For the same quarter last year, the
company reported a loss of 27 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Iveric Bio Inc
is $21.5​, about 17.6% above​ its last closing price
of $17.72. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.26       -0.26      -0.32     Missed  -22.8
 Mar. 31 2021  -0.25       -0.25      -0.29     Missed  -16.5
 Dec. 31 2020              -0.26      -0.27     Missed  -5.5​
 Sep. 30 2020  -0.22       -0.22      -0.27     Missed  -23.6
 Jun.          -0.31​      -0.31      -0.32     Missed  -3.2​
 30​ 2020​                                              
 Mar. 31 2020  -0.39       -0.39      -0.28     Beat    28.2​
 Dec. 31 2019  -0.28       -0.28      -0.39     Missed  -39.3
 This summary was machine generated October 29 at 18:06 GMT.  All
figures in US dollars unless otherwise stated

Recent news on IVERIC bio

See all news